As of 2024-10-12, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -35.49 mil USD. CARA's TTM EBITDA according to its financial statements is -107.73 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.2x - 13.2x | 12.6x |
| Forward P/E multiples | 17.3x - 21.2x | 20.0x |
| Fair Price | (33.16) - (24.99) | (31.22) |
| Upside | -13332.7% - -10072.1% | -12556.7% |
| Date | EV/EBITDA |
| 2024-10-11 | 0.33 |
| 2024-10-10 | 0.33 |
| 2024-10-09 | 0.32 |
| 2024-10-08 | 0.33 |
| 2024-10-07 | 0.32 |
| 2024-10-04 | 0.32 |
| 2024-10-03 | 0.32 |
| 2024-10-02 | 0.31 |
| 2024-10-01 | 0.31 |
| 2024-09-30 | 0.30 |
| 2024-09-27 | 0.30 |
| 2024-09-26 | 0.31 |
| 2024-09-25 | 0.32 |
| 2024-09-24 | 0.31 |
| 2024-09-23 | 0.30 |
| 2024-09-20 | 0.30 |
| 2024-09-19 | 0.30 |
| 2024-09-18 | 0.31 |
| 2024-09-17 | 0.32 |
| 2024-09-16 | 0.32 |
| 2024-09-13 | 0.32 |
| 2024-09-12 | 0.32 |
| 2024-09-11 | 0.31 |
| 2024-09-10 | 0.31 |
| 2024-09-09 | 0.30 |
| 2024-09-06 | 0.29 |
| 2024-09-05 | 0.29 |
| 2024-09-04 | 0.29 |
| 2024-09-03 | 0.29 |
| 2024-08-30 | 0.27 |
| 2024-08-29 | 0.28 |
| 2024-08-28 | 0.28 |
| 2024-08-27 | 0.27 |
| 2024-08-26 | 0.27 |
| 2024-08-23 | 0.28 |
| 2024-08-22 | 0.28 |
| 2024-08-21 | 0.28 |
| 2024-08-20 | 0.28 |
| 2024-08-19 | 0.29 |
| 2024-08-16 | 0.29 |
| 2024-08-15 | 0.29 |
| 2024-08-14 | 0.29 |
| 2024-08-13 | 0.28 |
| 2024-08-12 | 0.29 |
| 2024-08-09 | 0.28 |
| 2024-08-08 | 0.28 |
| 2024-08-07 | 0.28 |
| 2024-08-06 | 0.27 |
| 2024-08-05 | 0.28 |
| 2024-08-02 | 0.28 |